Evidence map›Paper›PMID 42741297›Full record

ArticleACS medicinal chemistry letters2026

Changho Han, Upendra Rathnayake, Alison R Gregro, Julie L Engers, Christopher C Presley, Nathan D Schley, Analisa D Thompson Gray, Michael Bubser, Hyekyung P Cho, Alice L Rodriguez and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Changho HanWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID https://orcid.org/0000-0002-0832-7070
Upendra RathnayakeWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID https://orcid.org/0009-0003-9363-9937
Alison R GregroWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Julie L EngersWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID https://orcid.org/0009-0004-3654-5464
Christopher C PresleyWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Nathan D SchleyDepartment of Chemistry, Vanderbilt University, Nashville Tennessee 37232, United States.ORCID https://orcid.org/0000-0002-1539-6031
Analisa D Thompson GrayWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Michael BubserWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Hyekyung P ChoWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Alice L RodriguezWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID https://orcid.org/0000-0002-5244-5103
Valerie M KramlingerWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Olivier BoutaudWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Colleen M NiswenderWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID https://orcid.org/0000-0001-6009-8212
Carrie K JonesWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Darren W EngersWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Craig W LindsleyWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID https://orcid.org/0000-0003-0168-1445

Funding

Muscarinic receptor activators as novel antipsychotic agentsR01MH073676 · NIMH · VANDERBILT UNIVERSITY · PI Jerri Michelle Rook · 2006 to 2026
$9.3M
Selective M1 mAChR allosteric modulators for the treatment of schizophreniaR01MH082867 · NIMH · VANDERBILT UNIVERSITY · PI LINDSLEY, CRAIG · 2008 to 2017
$3.7M
Cellular and molecular analysis of startle modulationR01MH109498 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI GRANATO, MICHAEL · 2016 to 2020
$2.4M
Development of an mGlu2/4 heterodimer-selective allosteric modulatorR01MH108498 · NIMH · VANDERBILT UNIVERSITY · PI LINDSLEY, CRAIG, NISWENDER, COLLEEN M · 2016 to 2018
$1.5M
NIMH NIH HHS R01 MH073676NIMH NIH HHS R01 MH082867NIMH NIH HHS R01 MH108498NIMH NIH HHS R01 MH109498
6 · The paper itself

Abstract

Recently, we disclosed our M

Indexed as

cognitionde novo designhuman dose projectionmuscarinic acetylcholine receptor subtype 1 (M1)positive allosteric modulator (PAM)

Identifiers

PMID42741297
PMCPMC13573255

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.